Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China · Delayed Price · Currency is CNY 7.99
-0.16 (-1.96%)
Mar 9, 2026, 4:00 PM EDT
SHA:688189 Revenue
In the year 2025, Hunan Nucien Pharmaceutical had annual revenue of 141.93M CNY, down -46.09%. Hunan Nucien Pharmaceutical had revenue of 58.77M in the quarter ending December 31, 2025, with 382.77% growth.
Revenue
141.93M
Revenue Growth
-46.09%
P/S Ratio
15.79
Revenue / Employee
387.78K
Employees
319
Market Cap
2.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 141.93M | -121.36M | -46.09% |
| Dec 31, 2024 | 263.28M | -456.78M | -63.44% |
| Dec 31, 2023 | 720.06M | 21.24M | 3.04% |
| Dec 31, 2022 | 698.83M | -44.83M | -6.03% |
| Dec 31, 2021 | 743.66M | -285.48M | -27.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Tiansheng Pharmaceutical Group | 516.17M |
| Sailong Pharmaceutical Group | 244.84M |